Table 9.
Stratified analyses between CYP20A1 rs2043449 polymorphism and lung cancer susceptibility
| Variable |
CYP20A1 rs2043449
Adjusted OR (95%CI) P a Study Power |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CC | CT | TT | CC/CT vs TT | CC vs CT/TT | CC vs TT | |||||
| Sex | ||||||||||
| Male | 3.19 (0.64‐15.94) 0.158 | 1.42 (0.94‐2.16) 0.095 | 1.00 | 1.50 (1.00‐2.24) 0.049* | 0.916 | 3.04 (0.61‐15.17) 0.176 | 1.50 (1.03‐2.16) 0.033* | 0.123 | ||
| Female | 6.33e‐10 (0.00‐inf) 0.999 | 0.65 (0.30‐1.40) 0.270 | 1.00 | 0. 62 (0.29‐1.32) 0.211 | 0.00 (0.00‐inf) 0.999 | 0.60 (0.29‐1.25) 0.174 | ||||
| TNM Stage | ||||||||||
| I‐II | 2.09e‐9 (0.00‐inf) 0.999 | 0.95 (0.53‐1.72) 0.872 | 1.00 | 0.91 (0.50‐1.63) 0.743 | 2.11e‐9 (0.00‐inf) 0.999 | 0.87 (0.49‐1.52) 0.620 | ||||
| III‐IV | 2.93 (0.65‐13.25) 0.162 | 1.41 (0.92‐2.15) 0.119 | 1.00 | 1.47 (0.97‐2.23) 0.067 | 2.79 (0.62‐12.60) 0.182 | 1.47 (1.01‐2.15) 0.044* | 0.127 | |||
| Lymph node status | ||||||||||
| Positive | 1.85 (0.31‐11.2) 0.504 | 1.46 (0.92‐2.32) 0.106 | 1.00 | 1.50 (0.94‐2.32) 0.088 | 1.75 (0.29‐10.57) 0.544 | 1.44 (0.95‐2.18) 0.086 | ||||
| Negative | 2.91 (0.46‐18.22) 0.255 | 0.75 (0.39‐1.45) 0.399 | 1.00 | 0.84 (0.45‐1.57) 0.591 | 3.00 (0.48‐18.76) 0.241 | 0.95 (0.54‐1.65) 0.841 | ||||
| Type of cancer | ||||||||||
| SCC | 0.81 (0.08‐8.40) 0.862 | 1.34 (0.82‐2.21) 0.245 | 1.00 | 1.32 (0.81‐2.15) 0.272 | 0.78 (0.08‐8.04) 0.834 | 1.26 (0.80‐1.99) 0.326 | ||||
| AC | 1.07 (0.11‐10.51) 0.957 | 1.00 (0.58‐1.72) 0.999 | 1.00 | 1.00 (0.59‐1.71) 0.992 | 1.07 (0.11‐10.50) 0.957 | 1.01 (0.61‐1.65) 0.983 | ||||
| SCLC | 5.36 (1.06‐27.21) 0.043* | 0.979 | 1.14 (0.60‐2.18) 0.682 | 1.00 | 1.34 (0.74‐2.44) 0.335 | 5.27 (1.04‐26.66) 0.045* | 0.991 | 1.46 (0.87‐2.45) 0.148 | ||
* P ≤ 0.05 value indicates statistical significance; P a adjusted for age and sex.
Bold indicates the siginificant value P ≤ 0.05 and the value of study power>0.8
Abbreviations: AC, adenocarcinoma; CI, confidence interval; ORs, odds ratios; SCC, Squamous cell carcinoma; SCLC, small cell lung cancer; TNM, tumor‐lymph node‐metastasis.